Yeast two-hybrid methods and their applications in drug discovery.
暂无分享,去创建一个
[1] M. Bickle,et al. A RasGAP SH3 Peptide Aptamer Inhibits RasGAP-Aurora Interaction and Induces Caspase-Independent Tumor Cell Death , 2008, PloS one.
[2] P. Colas. The eleven-year switch of peptide aptamers , 2008, Journal of biology.
[3] S. Muyldermans,et al. Recent developments in engineering and delivery of protein and antibody therapeutics. , 2011, Current opinion in biotechnology.
[4] A. Vazquez,et al. Epstein–Barr virus and virus human protein interaction maps , 2007, Proceedings of the National Academy of Sciences.
[5] Chi P. Ndi,et al. A Novel Natural Product Compound Enhances cAMP-Regulated Chloride Conductance of Cells Expressing CFTRΔF508 , 2002, Molecular medicine.
[6] R. Brent,et al. Targeted modification and transportation of cellular proteins. , 2000, Proceedings of the National Academy of Sciences of the United States of America.
[7] G L French,et al. The continuing crisis in antibiotic resistance. , 2010, International journal of antimicrobial agents.
[8] T. Berg. Small-molecule inhibitors of protein-protein interactions. , 2008, Current opinion in drug discovery & development.
[9] A. Barabasi,et al. High-Quality Binary Protein Interaction Map of the Yeast Interactome Network , 2008, Science.
[10] Michael Gribskov,et al. A Physical Interaction Network of Dengue Virus and Human Proteins* , 2011, Molecular & Cellular Proteomics.
[11] A. Reymond,et al. p16 proteins from melanoma-prone families are deficient in binding to Cdk4. , 1995, Oncogene.
[12] N. Saxena,et al. RAS: Target for Cancer Therapy , 2008, Cancer investigation.
[13] J. Camarero,et al. Protein Microarrays: Novel Developments and Applications , 2010, Pharmaceutical Research.
[14] H. Lehrach,et al. A Human Protein-Protein Interaction Network: A Resource for Annotating the Proteome , 2005, Cell.
[15] M. Baccarini,et al. Raf kinases in cancer–roles and therapeutic opportunities , 2011, Oncogene.
[16] J. Rain,et al. Characterization of single chain antibody targets through yeast two hybrid , 2010, BMC biotechnology.
[17] P. Aloy,et al. Unveiling the role of network and systems biology in drug discovery. , 2010, Trends in pharmacological sciences.
[18] Michael Albers,et al. Automated Yeast Two-hybrid Screening for Nuclear Receptor-interacting Proteins*S , 2005, Molecular & Cellular Proteomics.
[19] A. Barabasi,et al. Interactome Networks and Human Disease , 2011, Cell.
[20] John P. Overington,et al. How many drug targets are there? , 2006, Nature Reviews Drug Discovery.
[21] Philippe Roche,et al. Chemical and structural lessons from recent successes in protein-protein interaction inhibition (2P2I). , 2011, Current opinion in chemical biology.
[22] C. Rudin,et al. A phase IIa study of ABT-263 in patients with relapsed small-cell lung cancer (SCLC). , 2010 .
[23] Uwe Sauer,et al. From good old biochemical analyses to high-throughput omics measurements and back. , 2011, Current opinion in biotechnology.
[24] Jodi R Parrish,et al. Yeast two-hybrid contributions to interactome mapping. , 2006, Current opinion in biotechnology.
[25] Paul A. Bates,et al. Global topological features of cancer proteins in the human interactome , 2006, Bioinform..
[26] Nobuyoshi Sugaya,et al. Assessing the druggability of protein-protein interactions by a supervised machine-learning method , 2009, BMC Bioinformatics.
[27] Jonathan C. Fuller,et al. Predicting druggable binding sites at the protein-protein interface. , 2009, Drug discovery today.
[28] N. Hacohen,et al. A Physical and Regulatory Map of Host-Influenza Interactions Reveals Pathways in H1N1 Infection , 2009, Cell.
[29] Jonathan A. Cooper,et al. Identification of radicicol as an inhibitor of in vivo Ras/Raf interaction with the yeast two-hybrid screening system. , 1998, The Journal of antibiotics.
[30] M. Hirst,et al. A two-hybrid system for transactivator bait proteins , 2001, Proceedings of the National Academy of Sciences of the United States of America.
[31] S. Schreiber,et al. A yeast genetic system for selecting small molecule inhibitors of protein-protein interactions in nanodroplets. , 1997, Proceedings of the National Academy of Sciences of the United States of America.
[32] Igor Stagljar,et al. Two-hybrid technologies in proteomics research. , 2008, Current opinion in biotechnology.
[33] W. Marasco,et al. Intracellular antibodies (intrabodies) and their therapeutic potential. , 2008, Handbook of experimental pharmacology.
[34] Debjani Paul,et al. Label-free sub-picomolar protein detection with field-effect transistors. , 2010, Analytical chemistry.
[35] K. Gull,et al. A Protein-Protein Interaction Map of the Trypanosoma brucei Paraflagellar Rod , 2009, PloS one.
[36] M. Bickle,et al. Peptide aptamers for small molecule drug discovery. , 2009, Methods in molecular biology.
[37] Christopher L. McClendon,et al. Reaching for high-hanging fruit in drug discovery at protein–protein interfaces , 2007, Nature.
[38] Julie M. Sahalie,et al. An experimentally derived confidence score for binary protein-protein interactions , 2008, Nature Methods.
[39] A. Barabasi,et al. A Protein–Protein Interaction Network for Human Inherited Ataxias and Disorders of Purkinje Cell Degeneration , 2006, Cell.
[40] P. Chanda,et al. Identification and characterization of small molecule modulators of KChIP/Kv4 function. , 2005, Bioorganic & medicinal chemistry.
[41] S. Hawkins,et al. Chemical Genetics , 1973, Nature.
[42] Ariel S. Schwartz,et al. Cost effective strategies for completing the Interactome , 2008, Nature Methods.
[43] T. Blundell,et al. Targeting LMO2 with a peptide aptamer establishes a necessary function in overt T-cell neoplasia. , 2009, Cancer research.
[44] W. Abida,et al. Dexamethasone−Methotrexate: An Efficient Chemical Inducer of Protein Dimerization In Vivo , 2000 .
[45] R. Brent,et al. A eukaryotic transcriptional activator bearing the DNA specificity of a prokaryotic repressor , 1985, Cell.
[46] E. Golemis,et al. Resolving the network of cell signaling pathways using the evolving yeast two-hybrid system. , 2008, BioTechniques.
[47] S. Laurenson,et al. Development of peptide aptamer microarrays for detection of HPV16 oncoproteins in cell extracts. , 2011, Analytical biochemistry.
[48] B. de Chassey,et al. An Antiproliferative Genetic Screening Identifies a Peptide Aptamer That Targets Calcineurin and Up-regulates Its Activity* , 2007, Molecular & Cellular Proteomics.
[49] A. Barberis,et al. Quenching accumulation of toxic galactose-1-phosphate as a system to select disruption of protein-protein interactions in vivo. , 2004, BioTechniques.
[50] C. Rommel,et al. Decompartmentalizing target validation—thinking outside the pipeline boxes , 2006, Journal of Molecular Medicine.
[51] Olivier Sperandio,et al. Rationalizing the chemical space of protein-protein interaction inhibitors. , 2010, Drug discovery today.
[52] G. Kroemer,et al. Peptides and aptamers targeting HSP70: a novel approach for anticancer chemotherapy. , 2011, Cancer research.
[53] M. Bickle,et al. A Comparative Analysis of Perturbations Caused by a Gene Knock-out, a Dominant Negative Allele, and a Set of Peptide Aptamers*S , 2007, Molecular & Cellular Proteomics.
[54] Agrobacterium tumefaciens-mediated transformation of filamentous fungi , 1998, Nature Biotechnology.
[55] P. Colas,et al. High-throughput screening assays to discover small-molecule inhibitors of protein interactions. , 2008, Current drug discovery technologies.
[56] John P. Overington,et al. ChEMBL: a large-scale bioactivity database for drug discovery , 2011, Nucleic Acids Res..
[57] Hualiang Jiang,et al. The natural product Aristolactam AIIIa as a new ligand targeting the polo-box domain of polo-like kinase 1 potently inhibits cancer cell proliferation , 2009, Acta Pharmacologica Sinica.
[58] Julie A. Hines,et al. A proteome-wide protein interaction map for Campylobacter jejuni , 2007, Genome Biology.
[59] A. Colman-Lerner,et al. "Mutagenesis" by peptide aptamers identifies genetic network members and pathway connections. , 1999, Proceedings of the National Academy of Sciences of the United States of America.
[60] Yuren Wang,et al. A Dual Luciferase Multiplexed High-Throughput Screening Platform for Protein-Protein Interactions , 2003, Journal of biomolecular screening.
[61] Jan Tavernier,et al. Strategies towards high-quality binary protein interactome maps. , 2010, Journal of proteomics.
[62] Jingkai Yu,et al. Combining multiple positive training sets to generate confidence scores for protein–protein interactions , 2008, Bioinform..
[63] K. Lund,et al. Identification of protein interaction antagonists using the repressed transactivator two-hybrid system. , 2007, BioTechniques.
[64] John S Lazo,et al. Low molecular weight inhibitors of Myc–Max interaction and function , 2003, Oncogene.
[65] S. L. Wong,et al. Towards a proteome-scale map of the human protein–protein interaction network , 2005, Nature.
[66] Stanley Fields,et al. Interactive learning: Lessons from two hybrids over two decades , 2009, Proteomics.
[67] David P. Lane,et al. Translating p53 into the clinic , 2010, Nature Reviews Clinical Oncology.
[68] M. Vidal,et al. Edgetic perturbation models of human inherited disorders , 2009, Molecular systems biology.
[69] Sebastian Meier-Ewert,et al. A three-hybrid approach to scanning the proteome for targets of small molecule kinase inhibitors. , 2004, Chemistry & biology.
[70] P. Uetz,et al. The Binary Protein Interactome of Treponema pallidum – The Syphilis Spirochete , 2008, PloS one.
[71] Bruno O Villoutreix,et al. A novel druglike spleen tyrosine kinase binder prevents anaphylactic shock when administered orally. , 2008, The Journal of allergy and clinical immunology.
[72] B. Groner,et al. Monomeric Recombinant Peptide Aptamers Are Required for Efficient Intracellular Uptake and Target Inhibition , 2008, Molecular Cancer Research.
[73] E J Licitra,et al. A three-hybrid system for detecting small ligand-protein receptor interactions. , 1996, Proceedings of the National Academy of Sciences of the United States of America.
[74] Bernd Groner,et al. Peptide aptamer libraries. , 2008, Combinatorial chemistry & high throughput screening.
[75] P. Colas,et al. Inhibition of heat shock protein 27 (HspB1) tumorigenic functions by peptide aptamers , 2011, Oncogene.
[76] Philippe Roche,et al. Atomic Analysis of Protein-Protein Interfaces with Known Inhibitors: The 2P2I Database , 2010, PloS one.
[77] Jie Zhang,et al. Inhibitors of Ras/Raf-1 interaction identified by two-hybrid screening revert Ras-dependent transformation phenotypes in human cancer cells , 2002, Proceedings of the National Academy of Sciences of the United States of America.
[78] L. Hutchinson,et al. High drug attrition rates—where are we going wrong? , 2011, Nature Reviews Clinical Oncology.
[79] Caroline C. Friedel,et al. Analysis of Intraviral Protein-Protein Interactions of the SARS Coronavirus ORFeome , 2007, PloS one.
[80] W. Childers,et al. Disruption of Kv1.1 N-type inactivation by novel small molecule inhibitors (disinactivators). , 2008, Bioorganic & medicinal chemistry.
[81] S. Fields,et al. A novel genetic system to detect proteinprotein interactions , 1989, Nature.
[82] M. Vidal,et al. Hepatitis C virus infection protein network , 2008, Molecular systems biology.
[83] Anne-Claude Gavin,et al. Recent advances in charting protein-protein interaction: mass spectrometry-based approaches. , 2011, Current opinion in biotechnology.
[84] Peter Uetz,et al. Improving yeast two-hybrid screening systems. , 2008, Briefings in functional genomics & proteomics.
[85] S. Fields,et al. The two-hybrid system: a method to identify and clone genes for proteins that interact with a protein of interest. , 1991, Proceedings of the National Academy of Sciences of the United States of America.
[86] R. Brent,et al. Understanding gene and allele function with two-hybrid methods. , 1997, Annual review of genetics.
[87] Peter Uetz,et al. Improving the yeast two-hybrid system with permutated fusions proteins: the Varicella Zoster Virus interactome , 2010, Proteome Science.
[88] K. Shokat,et al. Chemical Genetics: Where Genetics and Pharmacology Meet , 2007, Cell.
[89] V. Tan,et al. First BRET-based screening assay performed in budding yeast leads to the discovery of CDK5/p25 interaction inhibitors. , 2011, Biotechnology journal.
[90] P. Secchiero,et al. Recent advances in the therapeutic perspectives of Nutlin-3. , 2011, Current pharmaceutical design.
[91] Julie M. Sahalie,et al. Supplementary Figure and Table Legends , 2022 .
[92] Roger Brent,et al. Genetic selection of peptide aptamers that recognize and inhibit cyclin-dependent kinase 2 , 1996, Nature.
[93] F. Hoppe-Seyler,et al. Isolation of peptides blocking the function of anti-apoptotic Livin protein , 2010, Cellular and Molecular Life Sciences.
[94] Robert W. Shafer,et al. Comparison of the Mechanisms of Drug Resistance among HIV, Hepatitis B, and Hepatitis C , 2010, Viruses.